FTSE 100 news / Companies and sectors / AstraZeneca / AstraZeneca files savolitinib-Tagrisso application with FDA
AstraZeneca files savolitinib-Tagrisso application with FDA
+5.7 positive
AstraZeneca seeks FDA approval for savolitinib plus Tagrisso, drawing valuation commentary.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| Medical Daily | 1 | +7.5 |
| finance.biggo.com | 1 | +6.7 |
| Traders Union | 1 | +5.8 |
| Simply Wall Street | 1 | +5.0 |
| Yahoo Finance | 1 | +5.0 |
| Kalkine Media | 1 | +4.2 |
Day by day
Friday 2 October 2026
Coverage discusses the Orpathys plus Tagrisso FDA application.
- +5.8 ORPATHYS plus TAGRISSO FDA application supports AstraZeneca stock after support test
FDA application for Orpathys plus Tagrisso supports outlook. - +4.2 AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus
Oncology filing puts growth and valuation in focus.
Thursday 1 October 2026
AstraZeneca seeks FDA approval for savolitinib plus Tagrisso, drawing valuation commentary.
- +7.5 AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes
FDA filing for lung cancer combination, pipeline progress - +5.0 Is AstraZeneca (LSE:AZN) Undervalued As Its Lung Cancer Filing Draws Fresh Attention?
Valuation piece citing lung cancer filing attention - +5.0 Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?
Valuation piece following new FDA filing
Wednesday 30 September 2026
Hutchmed and AstraZeneca submitted a lung cancer drug application to the US FDA.
- +6.7 Hutchmed, AstraZeneca Submit Lung Cancer Drug Application for ORPATHYS-TAGRISSO Combination to U.S. FDA
US FDA application submitted for lung cancer combination.